Holen Sie sich die Stockscreener-App
2.33
4.02%
0.09
Handel nachbörslich:
2.25
-0.08
-3.43%
Schlusskurs vom Vortag:
$2.24
Offen:
$2.27
24-Stunden-Volumen:
1.35M
Relative Volume:
0.96
Marktkapitalisierung:
$165.83M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-0.8727
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
+18.88%
1M Leistung:
+4.48%
6M Leistung:
-27.19%
1J Leistung:
-59.12%
1-Tages-Spanne:
$2.245
$2.4781
1-Wochen-Bereich:
$2.00
$2.94
52-Wochen-Spanne:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.33 | 159.42M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Why is C4 Therapeutics Inc. stock going downDay Trading 5x Gain Picks - mustnews.co.kr
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Why C4 Therapeutics Inc. stock attracts strong analyst attentionStock Forecast Tools for Retail Traders - Newser
What earnings revisions data tells us about C4 Therapeutics Inc.Free Growth Based Investment Plan Guidance - Newser
Real time breakdown of C4 Therapeutics Inc. stock performanceDaily Pick Forecast with Entry Zones - Newser
Is C4 Therapeutics Inc. stock ready for a breakoutTechnical Trade Plan with Entry Checklist - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsWeekly Gain Forecast with Momentum Indicators - Newser
New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Smart Swing Picks with Confirmed Signals - Newser
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 2025 Q2 Earnings Widened Losses Amid Mixed Price Performance - AInvest
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M - simplywall.st
C4 Therapeutics Reports Q2 2025 Financial Results - TipRanks
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Q2 2025 Financial Results: Revenue Down to $6.5M, Cash Position at $223M - AInvest
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
C4 Therapeutics, Inc. SEC 10-Q Report - TradingView
C4 Therapeutics reports Q2 2025 results, cemsidomide Phase 1 data accepted at IMS. - AInvest
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
C4 Therapeutics shares rise 1.02% premarket after Ono Pharmaceutical's ESG index selection. - AInvest
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What drives C4 Therapeutics Inc. stock priceBuild wealth faster with disciplined trading - Jammu Links News
Is it the right time to buy C4 Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
What makes C4 Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
What is C4 Therapeutics Inc. company’s growth strategyMaximize returns with strategic trading plans - Jammu Links News
When is C4 Therapeutics Inc. stock expected to show significant growthGet timely alerts on top market movers - Jammu Links News
What is the dividend policy of C4 Therapeutics Inc. stockUnlock daily trading alerts for profits - Jammu Links News
Is C4 Therapeutics Inc. stock overvalued or undervaluedSuperior stock growth - Jammu Links News
Why is C4 Therapeutics Inc. stock attracting strong analyst attentionUnmatched market performance - Jammu Links News
Is C4 Therapeutics Inc. a growth stock or a value stockFree Capital Allocation Plans - Jammu Links News
What are C4 Therapeutics Inc. company’s key revenue driversGet alerts on high-potential market moves - Jammu Links News
What is the risk reward ratio of investing in C4 Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
What are the latest earnings results for C4 Therapeutics Inc.Invest confidently with professional market insights - Jammu Links News
What are analysts’ price targets for C4 Therapeutics Inc. in the next 12 monthsInvest confidently with market-leading analysis - Jammu Links News
Here's What Analysts Are Forecasting For C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its First-Quarter Results - 富途牛牛
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):